Stock News

Indoco Remedies announced receipt of approval of its ANDA for Succinylcholine Chloride Injection USP 200 mg/ 10 ml (20 mg/ml) Multidose vial, therapeutically equivalent to the Reference Listed Drug (RLD) Quelicin Injection of Hospira, Inc.

Succinylcholine Chloride Injection is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

The US market size of Succinylcholine Chloride Injection is of 72 million USD (6 million vials), as per IMS data for the year ending March, 2020.

The product is being used for some patients infected with Corona virus (COVID19).

At 12.40 pm, Indoco Remedies was trading at Rs. 210.15, down by 0.14%, with a volume of 8465 shares on the BSE.

ITC enters into a Share Purchase Agreement to acquire 100% equity share capital of Sunrise Foods Pvt.

Glenmark Pharmaceuticals has announced a new randomized, open-label study to test the combined efficacy of two antiviral drugs Favipiravir and Umifenovir as a potential COVID-19 treatment strategy. The two antiviral drugs have different mechanism of action, and their combination may demonstrate improved treatment efficacy by effectively tackling high viral loads in patients during early stage of disease.

At 10.45 am, Glenmark Pharmaceuticals was trading at Rs. 355.90, up by 0.91%, with a volume of 1.72 lakh shares on the BSE.

Shares of Bharti Airtel slipped over 5% touching to Rs. 561.1, as promoter Bharti Telecom has announced to sell 2.75% stake in the company for $1 billion through a private placement at a floor price of Rs. 558 per share as per report.

At 9.44 am, Bharti Airtel was trading at Rs. 572.95, down by 3.38%, with a volume of 1657.49 lakh shares on the BSE.

Pharma major Lupin announced that it has received approval for its Trientine Hydrochloride Capsules USP, 250 mg, from the United States Food and Drug

Administration (USFDA), to market a generic equivalent of Syprine® Capsules, 250 mg, of Bausch Health US, LLC. The product would be manufactured at Lupin’s Nagpur (Unit 1) facility, India.

Trientine Hydrochloride Capsules USP, 250 mg, are indicated in the treatment of patients with Wilson’s disease who are intolerant of penicillamine.

Trientine Hydrochloride Capsules USP had an annual sales of approximately USD 86 million in the US.

At 1.56 pm, Lupin was trading at Rs. 893.35, up by 0.86%, with a volume of 0.49 lakh shares on the BSE.